5-Fluorouracil: mechanisms of action and clinical strategies
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
5-fluorouracil (5-FU) is widely used in the treatment of cancer. Over the past 20 years, increased understanding of the mechanism of action of 5-FU has led to the development of strategies that increase its anticancer activity. Despite these advances, drug resistance remains a significant limitation to the clinical use of 5-FU. Emerging technologies, such as DNA microarray profiling, have the potential to identify novel genes that are involved in mediating resistance to 5-FU. Such target genes might prove to be therapeutically valuable as new targets for chemotherapy, or as predictive biomarkers of response to 5-FU-based chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“5-FU exerts its anti-cancer effects by inhibiting thymidylate synthase (TS) and incorporating its metabolites into RNA and DNA [4].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“5-FU mainly destroys the deoxynucleotide pool required for DNA replication by inhibiting thymidylate synthase (TS), and mixes its metabolites into RNA and DNA to exert anti-tumor effects [4,127].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“Several studies have shown that the high expression of TS is a crucial determinant of CRC resistance to 5-FU”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“and 5-FU intervention can also increase the expression of TS [4,9,10].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [4]
In the citing paper
“MutSα recognizes and associates with FdU:G mismatch pairs in an in vitro binding experiment”
From Functional interplay between ATM/ATR-mediated DNA damage response and DNA repair pathways in oxidative stress (2014) · cites this paper as [210]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.
Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143
A gene expression database for the molecular pharmacology of cancer
Scherf, U., Ross, D. T., Waltham, M., Smith, L. H., Lee, J. K., Tanabe, L., Kohn, K. W., Reinhold, W. C., Myers, T. G., Andrews, D. T., et al. (2000) · Nature Genetics · doi:10.1038/73439 · Cited by 1,450
Giacchetti, S., Perpoint, B., Zidani, R., Le Bail, N., Faggiuolo, R., Focan, C., Chollet, P., Llory, J. F., Letourneau, Y., Coudert, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.136 · Cited by 1,403
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“Irinotecan is a topoisomerase I inhibitor and is active in the first- and second-line treatment of advanced colorectal cancer, in which it has shown improved survival and quality of life when compared with best supportive care in patients who have failed 5-FU/L”
Miwa, M., Ura, M., Nishida, M., Sawada, N., Ishikawa, T., Mori, K., Shimma, N., Umeda, I., & Ishitsuka, H. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00058-6 · Cited by 1,240
(1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.6.896 · Cited by 1,189
Hoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130
Research works printed but not linked: 2
- Rutman, R. J., Cantarow, A. & Paschkis, K. E. Studies on 2-acetylaminofluorene carcinogenesis: III. The utilization of uracil-2-C14 by pre–neoplastic rat liver. Cancer Res. 14, 119 (1954).
- Jackson, R. C. & Grindley, G. B. The Biochemical Basis for Methotrexate Cytotoxicity (eds Sirotnak, F. M., Burchall, J. J., Ensminger, W. D. & Montgomery, J. A.) 289–315 (Academic, New York, 1984).
Cited by
Items 501–600 of 1,028
Wu, J., Gan, Y., Li, M., Chen, L., Liang, J.-L., Zhuo, J.-Y., Luo, H., Xu, N., Wu, X. Y., Wu, Q., et al. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.109883 · Cited by 91
Elrebehy, M. A., Al-Saeed, S., Gamal, S., El‐Sayed, A., Ahmed, A. A., Waheed, O., Ismail, A., El‐Mahdy, H. A., Sallam, A.-A. M., & Doghish, A. S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.06.134 · Cited by 86
Inorganic nanolayers: structure, preparation, and biomedical applications
Bullo, S., & Hussein, M. Z. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s72330 · Cited by 91
Loading and release of 5-fluorouracil from HY zeolites with varying SiO2/Al2O3 ratios
Datt, A., Burns, E. A., Dhuna, N. A., & Larsen, S. C. (2012) · Microporous and Mesoporous Materials · doi:10.1016/j.micromeso.2012.09.011 · Cited by 85
Ciccolini, J., Mercier, C., Blachon, M. F., Favre, R., Durand, A., & Lacarelle, B. (2004) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/j.1365-2710.2004.00569.x · Cited by 83
“5-Fluorouracil (5-FU) is still a mainstay in the treatment of various solid tumours such as colorectal, head and neck, and breast cancers (1).”
BackgroundReactive gliosis in the adult zebrafish retina
Thomas, J. L., Ranski, A. H., Morgan, G. W., & Thummel, R. (2015) · Experimental Eye Research · doi:10.1016/j.exer.2015.09.017 · Cited by 95
Targeting nuclear thymidylate biosynthesis
Chon, J., Stover, P. J., & Field, M. S. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.11.005 · Cited by 83
“(Longley et al., 2003), and increased TYMS gene expression is associatedwith poor response to 5-FU treatment (Bathe et al.”
InfluentialRusso, A., Saide, A., Cagliani, R., Cantile, M., Botti, G., & Russo, G. (2016) · Scientific Reports · doi:10.1038/srep38369 · Cited by 82
Boisdron‐Celle, M., Capitain, O., Faroux, R., Borg, C., Metges, J. P., Galais, M., Kaassis, M., Bennouna, J., Bouhier‐Leporrier, K., François, É., et al. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.02.008 · Cited by 85
“The published literature suggests that approximately 2 million patients receive 5-FU worldwide each year, with approximately 250,000 to 300,000 patients in the United States receiving 5-FU–based regimens [1].”
BackgroundDeng, S., Wu, D., Li, L., Li, J., & Xu, Y. X. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00294-5 · Cited by 82
“5-FU is a chemotherapeutic drug that is widely used in the treatment of colon, stomach, esophagus, and other digestive system tumors [3, 4].”
BackgroundChen, L., She, X., Wang, T., He, L., Shigdar, S., Duan, W., & Kong, L. (2015) · Nanoscale · doi:10.1039/c5nr03527a · Cited by 82
McQuade, R. M., Stojanovska, V., Donald, E. L., Abalo, R., Bornstein, J. C., & Nurgali, K. (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12890 · Cited by 85
A DFT study of 5-fluorouracil adsorption on the pure and doped BN nanotubes
Soltani, A., Mohammad Taghi, B. A. E. I., Lemeski, E. T., Kaveh, S., & Balakheyli, H. (2015) · Journal of Physics and Chemistry of Solids · doi:10.1016/j.jpcs.2015.06.008 · Cited by 82
Hosseinifar, T., Sheybani, S., Abdouss, M., Hassani Najafabadi, S. A., & Shafiee Ardestani, M. (2018) · Journal of Biomedical Materials Research Part A · doi:10.1002/jbm.a.36242 · Cited by 81
“It has been reported that up to 85% of injected 5fluorouracil (5-FU), is quickly converted by Dihydropyrimidine dehydrogenase to inactive agent, resulting in a half-life of 10–15 min for 5-FU (21-25).”
BackgroundYang, Y., Ma, L., Xu, Y., Liu, Y., Li, W., Cai, J., & Zhang, Y. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2675-x · Cited by 80
Cooperation between chemotherapy and immunotherapy in gastroesophageal cancers
Davern, M., & Lysaght, J. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.09.014 · Cited by 83
“Leucovorin enhances the binding of 5-FU to thymidylate synthetase and prolongs the half-life of 5-FU in vivo [6].”
BackgroundHernández‐Vargas, H., Ballestar, E., Carmona‐Sáez, P., von Kobbe, C., Bañón‐Rodríguez, I., Esteller, M., Moreno‐Bueno, G., & Palacios, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.21938 · Cited by 83
5-Fluorouracil delivery from metal-ion mediated molecularly imprinted cryogel discs
Çetin, K., & Deni̇zli̇, A. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.12.038 · Cited by 81
Pan, W.-R., Chen, P., Chen, Y.-L. S., Hsu, H.-C., Lin, C.-C., & Chen, W.-J. (2013) · Journal of Dairy Science · doi:10.3168/jds.2013-7285 · Cited by 86
“In general, the main curative therapies for gastric cancer are surgery and chemotherapy, which are generally only successful if the cancer is diagnosed at an early stage (Baeza et al., 2001; Longley et al., 2003; Cascinu et al., 2004).”
BackgroundMallikarjuna Reddy, K., Ramesh Babu, V., Krishna Rao, K. S. V., Subha, M. C. S., Chowdoji Rao, K., Sairam, M., & Aminabhavi, T. M. (2008) · Journal of Applied Polymer Science · doi:10.1002/app.27305 · Cited by 81
Leteurtre, E., Gouyer, V., Rousseau, K., Moreau, O. K., Barbat, A., Swallow, D. M., Huet, G., & Lesuffleur, T. (2004) · Biology of the Cell · doi:10.1016/j.biolcel.2003.12.005 · Cited by 90
“We had observed that the long-term treatment of HT-29 cells with 5-fluorouracil (5-FU), the main chemotherapeutic agent for the treatment of colorectal cancer, or with methotrexate (MTX), an agent previously used to synergize with 5-FU (Longley et al., 2003), resulted in the selection of sub-populations of resistant c…”
BackgroundCholine Kinase Down-regulation Increases the Effect of 5-Fluorouracil in Breast Cancer Cells
Mori, N., Glunde, K., Takagi, T., Raman, V., & Bhujwalla, Z. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2728 · Cited by 81
“However, none of the genes directly involved in 5-FU metabolism, such as dihydropyrimidine dehydrogenase, thymidine phosphorylase, thymidylate synthase, human concentrative nucleoside transporter 1, or uridine phosphorylase, among others (28), were differentially expressed in MDA-MB-231 cells transiently transfected w…”
BackgroundYang, C. G., Ciccolini, J., Blesius, A., Dahan, L., Bagarry-Liegey, D., Brunet, C., Varoquaux, A. D., Frances, N., Marouani, H., Giovanni, A., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1282-4 · Cited by 81
“Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme that detoxifies 5-FU in the liver [ 14 , 18].”
BackgroundSystemic treatment for metastatic colorectal cancer in the era of precision medicine
Sandhu, J. S., Lavingia, V. K., & Fakih, M. (2019) · Journal of Surgical Oncology · doi:10.1002/jso.25421 · Cited by 86
“Since the late 1950s, 5‐fluorouracil (5‐FU) has become the cornerstone of treatment of colorectal cancers.(2) Infusional 5‐FU has been associated with fewer side effects than bolus administration and has resulted in a more favorable clinical outcome, whether administered as monotherapy or in combination with systemic…”
BackgroundTakotsubo cardiomyopathy in cancer patients
Desai, A. P., Noor, A., Joshi, S., & Kim, A. S. (2019) · Cardio-Oncology · doi:10.1186/s40959-019-0042-9 · Cited by 97
Hu, W., Chan, G. K.-L., Duan, R., Wang, H., Kong, X., Dong, T. T.-X., & Tsim, K. W. K. (2019) · Cancers · doi:10.3390/cancers11121828 · Cited by 82
“5-Fluorouracil (5-FU) is one of the most commonly-used and inexpensive chemotherapeutic agents for CRC treatment [13,14], which irreversibly suppresses the synthase of thymidylate, leading to a shortage of DNA synthesis [15].”
BackgroundPetreni, A., Bonardi, A., Lomelino, C. L., Osman, S. M., ALOthman, Z. A., Eldehna, W. M., El-Haggar, R. S., McKENNA, R. V., Nocentini, A., & Supuran, C. T. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112112 · Cited by 80
Pharmacogenomics of 5-fluorouracil in colorectal cancer: review and update
Xie, P., Mo, J., Liu, J., Li, X., Tan, L., Zhang, W., Zhou, H., & Liu, Z. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00529-1 · Cited by 85
“Since TS is a pharmacological target for 5-FU, its high expression represents an important factor in 5-FU resistance [50].”
BackgroundLanthanide complexes as anticancer agents: A review
Chundawat, N. S., Jadoun, S., Zarrintaj, P., & Chauhan, N. P. S. (2021) · Polyhedron · doi:10.1016/j.poly.2021.115387 · Cited by 86
Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance
Liu, Y., Ao, X., Wang, Y., Li, X., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.841411 · Cited by 90
Self‐Heating Multistage Microneedle Patch for Topical Therapy of Skin Cancer
Shao, J., Li, X., Li, Y., Lin, J., & Huang, P. (2024) · Advanced Materials · doi:10.1002/adma.202308217 · Cited by 86
Inflammatory intestinal damage induced by 5-fluorouracil requires IL-4
Soares, P. M. G., Mota, J. M., de Souza, E. P., Justino, P. F. C., Franco, Á. X., Cunha, F. Q., Ribeiro, R. A., & de Souza, M. H. L. P. (2012) · Cytokine · doi:10.1016/j.cyto.2012.10.003 · Cited by 80
“The antimetabolite agent 5-fluorouracil (5-FU) has been used in the treatment of a range of cancers and can induce intestinal damage, referred to as intestinal mucositis [3].”
BackgroundTargeting platelet-derived endothelial cell growth factor/thymidine phosphorylase for cancer therapy
Liekens, S., Bronckaers, A., Pérez‐Pérez, M., & Balzarini, J. M. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.05.008 · Cited by 84
Alexander, W. G., Wisecaver, J. H., Rokas, A., & Hittinger, C. T. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1517242113 · Cited by 85
“parisii TK, indeed encode active nucleoside kinases, providing a likely drug target with a known mechanism of action (38, 39).”
BackgroundRaz, S., Stark, M., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.004 · Cited by 86
Attia, Y. M., El‐Kersh, D. M., Wagdy, H. A., & Elmazar, M. M. (2018) · Scientific Reports · doi:10.1038/s41598-018-35083-2 · Cited by 84
Koehler, S. E., & Ladner, R. D. (2004) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)05645-1 · Cited by 50
“To inhibit TS, we used FUdR, which is readily converted to the active metabolite FdUMP yet avoids the potential RNA effects that may be introduced by using 5-FU (Canman et al., 1992; Longley et al., 2003).”
High resolution mapping of modified DNA nucleobases using excision repair enzymes
Bryan, D. S., Ransom, M., Adane, B., York, K., & Hesselberth, J. R. (2014) · Genome Research · doi:10.1101/gr.174052.114 · Cited by 82
“Thymidylate synthase is a major target of anti-metabolite drugs, such as pemetrexed and 5- fluorouracil, which inhibit TTP production by thymidylate synthase and simultaneously increase dUMPanddUTP levels (Longley et al. 2003).”
BackgroundFazzone, W., Wilson, P. M., LaBonte, M. J., Lenz, H., & Ladner, R. D. (2009) · International Journal of Cancer · doi:10.1002/ijc.24403 · Cited by 80
“Despite these advancements, the response rates for chemotherapy in patients with metastatic colon cancer remains only 50%.(1) TS overexpression is a well-documented mechanism of resistance to 5-FU-based therapy in colon cancer.”
BackgroundOverman, M. J., Varadhachary, G., Kopetz, S., Thomas, M. B., Fukushima, M., Kuwata, K., Mita, A., Wolff, R. A., Hoff, P. M., Xiong, H. Q., et al. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9142-3 · Cited by 79
“The delivery of 5-FU as a continuous infusion or as a prodrug in combination with various inhibitors of 5-FU degradation, such as UFT and S1, has improved 5-FU activity by increasing the cellular exposure of cancer cells to 5-FU [4].”
BackgroundHydrogen–water enhances 5-fluorouracil-induced inhibition of colon cancer
Runtuwene, J., Amitani, H., Amitani, M. S., Asakawa, A., Cheng, K., & Inui, A. (2015) · PeerJ · doi:10.7717/peerj.859 · Cited by 83
Selective depletion of metastatic stem cells as therapy for human colorectal cancer
Céspedes, M. V., Unzueta, U., Aviñó, A. M., Gallardo, A., Álamo, P., Sala, R., Sánchez‐Chardi, A., Casanova, I., Mangues, M. A., Pousa, A. L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201708772 · Cited by 83
“In colorectal cancer (CRC), as in other tumor types, adjuvant therapy controls metastases and prolongs survival at the expense of high toxicity; however, metastases remain the primary cause of death (Schrag, 2004; Mehlen & Puisieux, 2006; Spano et al, 2012; Riihimäki et al, 2016).”
BackgroundCancer drug resistance: A fleet to conquer
Hussain, S., Singh, A., Nazir, S. U., Tulsyan, S., Khan, A., Kumar, R., Bashir, N., Tanwar, P., & Mehrotra, R. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28782 · Cited by 86
“Examples of such drug inactivation are ‐ 5‐fluorouracil and pemetrexed, which work by posttranscriptionally upregulating thymidylate synthase expression and triggering negative feedback that results in the inhibition at the translational level of enzymes responsible for mRNA synthesis.(6) Genomic amplification of andr…”
BackgroundKnikman, J. E., Gelderblom, H. A. J., Beijnen, J. H., Cats, A., Guchelaar, H., & Henricks, L. M. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2069 · Cited by 79
“Afterward, α-fluoro-β-ureidopropionic and α-fluoro-β-alanine (FBAL) are formed, which are excreted through the urine with the remaining ~ 10% of 5-FU.(1,7)”
BackgroundSteel, T. R., Walsh, F. P., Wieczorek, A., Hanif, M., & Hartinger, C. G. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.213890 · Cited by 83
A review of FDA approved drugs and their formulations for the treatment of breast cancer
Chaurasia, M., Singh, R., Sur, S., & Flora, S. J. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1184472 · Cited by 93
“, 2019), Folate-tagged chitosan-functionalized gold nanoparticles (Longley et al., 2003; Akinyelu and Singh, 2019), 5- fluorouracil-loaded calcium phosphate nanoparticles (Bhadra et al.”
Background5-Fluorouracil-Induced Changes of Intestinal Integrity Biomarkers in BALB/C Mice
Song, M., Park, M., & Sung, M. (2013) · Journal of Cancer Prevention · doi:10.15430/jcp.2013.18.4.322 · Cited by 81
“through fluorodeoxyuridine monophosphate (FdUMP) and fluorouridine triphosphate (FUTP).(3,4) The major side effects of 5-FU include myelosuppression, diarrhea, cardiotoxicity, dermatitis, and mucositis.”
BackgroundDelivery of Floxuridine Derivatives to Cancer Cells by Water-Soluble Organometallic Cages
Yi, J. W., Barry, N. P. E., Furrer, M. A., Zava, O., Dyson, P. J., Therrien, B., & Kim, B. H. (2012) · Bioconjugate Chemistry · doi:10.1021/bc200472n · Cited by 79
Marcuello, E., Altés, A., Menoyo, A., del Rı́o, E., & Baiget, M. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0089-1 · Cited by 79
“5-Fluorouracil (5-FU), a drug of choice for the treatment of patients with metastatic colorectal cancer, exerts its anticancer effect through the inhibition of thymidylate synthase (TS) [10].”
BackgroundLei, L., Liu, X., Guo, S., Tang, M.-F., Cheng, L., & Tian, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.017 · Cited by 80
Oncogenic NRAS, KRAS, and HRAS Exhibit Different Leukemogenic Potentials in Mice
Parikh, C., Subrahmanyam, R., & Ren, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0778 · Cited by 79
“The blot was stripped with 0.1% boiling SDS solution and reprobed with 32P-labeled 1.4 kb irf-4 DNA fragment as a loading control.”
BackgroundInfluentialZhang, Q., Zhou, H., Zhai, S., & Yan, B. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791208983 · Cited by 88
Terranova-Barberio, M., Roca, M. S., Zotti, A. I., Leone, A., Bruzzese, F., Vitagliano, C., Scognamiglio, G., Russo, D., D’Angelo, G., Franco, R., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6802 · Cited by 88
“The second, 5-fluorouridine triphosphate (FUTP), inhibits RNA and protein synthesis by competing with uridine-triphosphate for incorporation into the RNA strand [2, 5].”
Lopes-Costa, E., Abreu, M., Gargiulo, D., Rocha, E., & Ramos, A. A. (2017) · Journal of Toxicology and Environmental Health, Part A · doi:10.1080/15287394.2017.1357297 · Cited by 77
“TS inhibition results in blockade of DNA synthesis, induction of DNA damage, cell cycle arrest, and apoptosis (Nita et al. 1998; Longley, Harkin, and Johnston 2003; De Angelis et al. 2006; Li et al. 2009; Kim et al. 2013).”
BackgroundRecent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment
Gmeiner, W. H. (2024) · Cancers · doi:10.3390/cancers16051029 · Cited by 78
“5-Fluororuracil (5-FU) was introduced into the clinic >60 years ago, and its use in the adjuvant setting in combination with folinic acid (leucovorin (LV)) was shown to decrease the risk for disease recurrence for patients with primary colon cancer [8,9].”
BackgroundFloxuridine Homomeric Oligonucleotides “Hitchhike” with Albumin In Situ for Cancer Chemotherapy
Jin, C. Y., Zhang, H., Zou, J., Liu, Y., Zhang, L., Li, F., Wang, R., Xuan, W., Ye, M., & Tan, W. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201804156 · Cited by 78
Pourmadadi, M., Ahmadi, M., Abdouss, M., Yazdian, F. A., Rashedi, H., Nigjeh, M. N., & Hesari, Y. (2021) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2021.102849 · Cited by 78
Effects of Zeolite as a Drug Delivery System on Cancer Therapy: A Systematic Review
Hao, J., Milašin, I. S., Eken, Z. B., Mravak‐Stipetić, M., Pavelić, K., & Özer, F. (2021) · Molecules · doi:10.3390/molecules26206196 · Cited by 83
“5-FU inhibits the activity of thymidylate synthase and incorporates its metabolites into RNA and DNA, thereby exerting anticancer effects [89].”
BackgroundDarroudi, M., Gholami, M., Rezayi, M., & Khazaei, M. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-021-01150-6 · Cited by 84
“5-FU is a fluorinated pyrimidine analog with demonstrated antitumor activity against adenocarcinomas arising in the gastrointestinal tract and breast cancer and ovary and against squamous cell carcinomas arising in the cell to 5-fluorodexyuridine monophosphate [88].”
BackgroundDrug delivery using biocompatible covalent organic frameworks (COFs) towards a therapeutic approach
Ghosh, P., & Banerjee, P. (2023) · Chemical Communications · doi:10.1039/d3cc01829f · Cited by 82
Breast Cancer Medications and Vision: Effects of Treatments for Early-stage Disease
Eisner, A., & Luoh, S. (2011) · Current Eye Research · doi:10.3109/02713683.2011.594202 · Cited by 79
Self-assembly of a 5-fluorouracil-dipeptide hydrogel
Sun, Y., Kaplan, J. A., Shieh, A., Sun, H., Croce, C. M., Grinstaff, M. W., & Parquette, J. R. (2016) · Chemical Communications · doi:10.1039/c6cc01195k · Cited by 83
Wang, J., Mouradov, D., Wang, X., Jorissen, R. N., Chambers, M., Zimmerman, L. J., Vasaikar, S. V., Love, C. G., Li, S., Lowes, K. N., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.008 · Cited by 82
Nanomedicine-based combination anticancer therapy between nucleic acids and small-molecular drugs
Huang, W., Chen, L., Kang, L., Jin, M., Sun, P., Xin, X., Gao, Z., & Bae, Y. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.004 · Cited by 77
Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
Song, M. J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i13.3843 · Cited by 77
Chalabi‐Dchar, M., Fenouil, T., Machon, C., Vincent, A., Catez, F., Marcel, V., Mertani, H. C., Saurin, J., Bouvet, P., Guitton, J., et al. (2021) · NAR Cancer · doi:10.1093/narcan/zcab032 · Cited by 93
“As a consequence, dUTP and 5-FdUTP can be misincorporated into DNA instead of dTTP, causing DNA damage (7).”
BackgroundInfluentialKeam, B., Im, S., Han, S., Ham, H. S., Kim, M. A., Oh, D., Lee, S., Kim, J. H., Kim, D., Kim, T., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-148 · Cited by 77
“TS, the target of 5-FU, has been investigated repeatedly in various aspects to predict the response to 5-FU, in terms of polymorphism, mRNA and protein expressions [10,16].”
BackgroundCancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
Pandha, H., Simpson, G. R., Relph, K., Melcher, A. A., & Harrington, K. J. (2016) · Oncolytic Virotherapy · doi:10.2147/ov.s66083 · Cited by 95
“As with other alkylating agents, its main mode of action is its ability to cross-link with the purine bases on the DNA.”
BackgroundInfluentialDevarasetty, M., Wang, E., Soker, S., & Skardal, A. (2017) · Biofabrication · doi:10.1088/1758-5090/aa7484 · Cited by 76
Silva, V. R., Corrêa, R. S., Santos, L. D. S., Soares, M. B. P., Batista, A. A., & Bezerra, D. P. (2018) · Scientific Reports · doi:10.1038/s41598-017-18639-6 · Cited by 78
Tumber, A., Collins, L. S., Petersen, K. D., Thougaard, A., Christiansen, S., Dejligbjerg, M., Jensen, P. B., Sehested, M., & Ritchie, J. W. A. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0374-7 · Cited by 77
“As discussed in the introduction, over-expression of TS in colorectal cancer in vitro is implicated in the mechanism of resistance to 5-FU [3, 4] and is a marker of poor prognosis clinically [ 5 , 28, 29].”
BackgroundKumar, D. N., Chaudhuri, A., Dehari, D., Shekher, A., Gupta, S. C., Majumdar, S., Krishnamurthy, S., Singh, S. K., Kumar, D. K., & Agrawal, A. K. (2022) · Life · doi:10.3390/life12081143 · Cited by 76
“The pyrimidine analog 5-FU is also the most potent cytotoxic agent, used to treat multiple solid tumors such as colorectal, breast, ovarian, and pancreatic cancer [12,13].”
BackgroundMattison, L. K., Fourie, J., Hirao, Y., Koga, T., Desmond, R. A., King, J. R., Shimizu, T., & Diasio, R. B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2020 · Cited by 76
“2, DPD) is the rate-limiting enzyme in uracil and 5-fluorouracil (5-FU) catabolism, converting >80% of an administered dose of 5-FU to inactive metabolites (1, 2).”
BackgroundMolecular Markers in the Treatment of Metastatic Colorectal Cancer
Wilson, P. M., LaBonte, M. J., & Lenz, H. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181e07738 · Cited by 88
Copija, A., Waniczek, D., Witkoś, A., Walkiewicz, K. W., & Nowakowska‐Zajdel, E. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010107 · Cited by 80
“5-FU is an analogue of uracil and its cytotoxic activity is the cause of the misincorporation of fluoronucleotides into nucleic acids by the active metabolites of 5-FU and in the inhibition of thymidylate synthase—an enzyme taking part in the synthesis of nucleotides [62].”
BackgroundTumorigenicity-associated characteristics of human iPS cell lines
Yasuda, S., Kusakawa, S., Kuroda, T., Miura, T., Tano, K., Takada, N., Matsuyama, S., Matsuyama, A., Nasu, M., Umezawa, A., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0205022 · Cited by 79
Sasaki, K., Tsuno, N. H., Sunami, E., Kawai, K., Hongo, K., Hiyoshi, M., Kaneko, M., Murono, K., Tada, N., Nirei, T., et al. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e328353f8c7 · Cited by 76
Chaudhry, G.-E.-S., Akim, A. M., Sung, Y. Y., & Muhammad, T. S. T. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2553-8_16 · Cited by 88
Phage release from biofilm and planktonic Staphylococcus aureus cells
Resch, A., Fehrenbacher, B., Eisele, K., Schaller, M., & Götz, F. (2005) · FEMS Microbiology Letters · doi:10.1016/j.femsle.2005.08.048 · Cited by 76
Liang, X. H., Tang, J., Liang, Y., Jin, R., & Cai, X. (2014) · Cell & Bioscience · doi:10.1186/2045-3701-4-10 · Cited by 84
“It exerts its anticancer effects through the inhibition of thymidylate synthase and the incorporation of its active metabolites, into RNA and DNA so as to influence the uracil metabolism and has been used in Phase II trial of combination chemotherapy for advanced cancers of the gallbladder [19,20].”
MethodMcNeill, D. R., Lam, W., DeWeese, T. L., Cheng, Y.-C., & Wilson, D. M. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0519 · Cited by 76
“Effect of ED on Sensitivity to the Antimetabolite 5Fluorouracil Recent evidence has suggested a role for BER capacity in cellular resistance to the antimetabolite 5-fluorouracil (5-FU), a drug that has been used in the clinic for decades to treat a variety of solid tumors, most notably colorectal cancer (26, 27).”
BackgroundControlled release of therapeutics using interpenetrating polymeric networks
Aminabhavi, T. M., Nadagouda, M. N., More, U. A., Joshi, S. D., Kulkarni, V. H., Noolvi, M. N., & Kulkarni, P. V. (2014) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2014.974871 · Cited by 80
“1 5-Fluorouracil The 5-FU is a widely used drug in clinical chemotherapy [28] for the treatment of solid tumors in breast [29], gastric [30] and pancreatic [31] cancers.”
BackgroundJoshi, P. N., Agawane, S. B., Athalye, M. C., Jadhav, V. H., Sarkar, D. M., & Prakash, R. (2017) · Materials Science and Engineering C · doi:10.1016/j.msec.2017.03.176 · Cited by 80
Downregulation of SIRT7 by 5-fluorouracil induces radiosensitivity in human colorectal cancer
Tang, M., Lu, X., Zhang, C., Du, C., Cao, L., Hou, T., Li, Z., Tu, B., Cao, Z., Li, Y., et al. (2017) · Theranostics · doi:10.7150/thno.18804 · Cited by 75
“For example, 5-FU-induced thymidylate synthase expression is a key determinant of 5-FU radiosensitivity (10, 11).”
BackgroundInfluentialChaudhury, S., Keegan, B. M., & Blagg, B. S. J. (2020) · Medicinal Research Reviews · doi:10.1002/med.21729 · Cited by 76
“chemotherapeutic agent that is used against various cancers including breast, bowel, skin, stomach, esophageal (gullet), and pancreatic.(113) Unfortunately, 5‐FU causes chemobrain and cognitive impairment as a major adverse event.”
BackgroundChemotherapy-induced gastrointestinal toxicity: Pathogenesis and current management
He, Y., Zheng, J., Ye, B., Dai, Y., & Nie, K. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115787 · Cited by 87
Kim, A.-Y., Kwak, J.-H., Je, N. K., Lee, Y.-H., & Jung, Y.-S. (2015) · Toxicological Research · doi:10.5487/tr.2015.31.2.151 · Cited by 75
“The structure of 5-FU is similar to those of pyrimidines in DNA and RNA; 5-FU inhibits thymidylate synthase and is incorporated into RNA and DNA, resulting in cytotoxicity and cell death (3).”
BackgroundActivation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors
Kalan, S., Amat, R., Schachter, M. M., Kwiatkowski, N. P., Abraham, B. J., Liang, Y., Zhang, T., Olson, C. M., Larochelle, S., Young, R. A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.09.056 · Cited by 75
“5-FU can be incorporated into DNA or RNA (Longley et al., 2003).”
BackgroundTargeting BER enzymes in cancer therapy
Visnes, T., Grube, M., Hanna, B., Benitéz‐Buelga, C., Cázares‐Körner, A., & Helleday, T. (2018) · DNA repair · doi:10.1016/j.dnarep.2018.08.015 · Cited by 82
Molecular Pathways: MicroRNAs as Cancer Therapeutics
Melo, S. A., & Kalluri, R. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2010 · Cited by 78
Iacopetta, B. J., Kawakami, K., & Watanabe, T. (2008) · International Journal of Clinical Oncology · doi:10.1007/s10147-008-0854-3 · Cited by 80
Molecular Mechanisms of Chemotherapy Resistance in Head and Neck Cancers
Kanno, Y., Chen, C.-Y., Lee, H.-L., Chiou, J.-F., & Chen, Y.-J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640392 · Cited by 86
“(i) FdUMP inhibits thymidylate synthase (TS) and results in dNTP imbalance which decreases levels of deoxythymidine triphosphate (dTTP) and increases levels of deoxyuridine triphosphate (dUTP) conversely (17, 19).”
BackgroundDNA repair, recombination, and damage signaling
Gartner, A., & Engebrecht, J. (2021) · Genetics · doi:10.1093/genetics/iyab178 · Cited by 77
“It has been proposed that the incorporation of these nucleotides does not directly lead to the formation of strand breaks, rather DNA breakage is likely generated by repair enzymes (Longley et al. 2003; Wyatt and Wilson 2009).”
BackgroundCD24‐dependent MAPK pathway activation is required for colorectal cancer cell proliferation
Wang, W., Wang, X., Peng, L., Deng, Q., Liang, Y., Qing, H., & Jiang, B. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01370.x · Cited by 80
Sakai, H., Sagara, A., Matsumoto, K., Hasegawa, S., Sato, K., Nishizaki, M., Shoji, T., Horie, S., Nakagawa, T., Tokuyama, S., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054788 · Cited by 77
“The antimetabolite agent 5-fluorouracil (5-FU) is most commonly used as a chemotherapy drug in the treatment of various cancers, including colorectal and breast cancers [1].”
BackgroundYen, L., Magnier, M., Weissleder, R., Stockwell, B. R., & Mulligan, R. C. (2006) · RNA · doi:10.1261/rna.2300406 · Cited by 77
“The full set of compounds included an annotated bioactive compound library (2036 compounds) (Root et al. 2003); a diversity library obtained from NINDS (1040 compounds) (Lunn et al. 2004); a collection of FDA-approved drugs (1000 compounds) (Rogers et al. 2002); a combinatorial library from…”
BackgroundPan, G., Jia, T.-T., Huang, Q.-X., Qiu, Y., Xu, J., Yin, P., & Liu, T. (2017) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2017.08.013 · Cited by 74
Du, P., Hu, C., Qin, Y., Zhao, J., Patel, R., Fu, Y., Zhu, M., Zhang, W., & Huang, G. (2019) · Journal of Oncology · doi:10.1155/2019/9325407 · Cited by 72
“By inhibiting essential biosynthetic processes and disrupting DNA and RNA synthesis, 5-FU treatment can significantly decrease the recurrence rate of tumors and improve PFS and OS of patients [27].”
BackgroundWang, M., Hu, H., Wang, Y., Huang, Q., Huang, R., Chen, Y., Ma, T., Qiao, T., Zhang, Q., Wu, H., et al. (2019) · Journal of Cancer · doi:10.7150/jca.32065 · Cited by 74
“Although many novel drugs have been developed for patients with advanced CRC, 5-fluorouracil (5-Fu) is still widely used as the first-line systemic chemotherapy, which targets thymidylate synthase to exert anticancer effects through blocking the normal synthesis of DNA and disrupting RNA processing [4].”
BackgroundA novel circular RNA circFN1 enhances cisplatin resistance in gastric cancer via sponging miR‐182‐5p
Huang, X., Zhang, Q., Hu, H., Jin, Y., Zeng, A., Xia, Y., & Xu, L. (2020) · Journal of Cellular Biochemistry · doi:10.1002/jcb.29641 · Cited by 78
“However, after several CDDP‐based treatment cycles, patients always acquire chemotherapy resistance, which limits the overall clinical efficacy of the treatment.(7,8) Clarification of the molecular mechanism responsible for CDDP resistance in GC will contribute to strategies designed to improve patient survival rates.”
Background
Metadata
- Authors
- Longley, D. B., Harkin, D. P., & Johnston, P. G.
- Affiliations
- Queen's University Belfast (GB)
- Corresponding author
- Johnston, Patrick G.
- ORCID
- Longley, Daniel B.
- Venue
- Nature Reviews Cancer
- Published
- 2003-05
- Volume
- 3
- Issue
- 5
- Pages
- 330-338
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1984328540
- Cited by
- 5,332
- References
- 111
- Citations by year
- 2026: 293 · 2025: 350 · 2024: 391 · 2023: 377 · 2022: 435 · 2021: 398 · 2020: 408 · 2019: 324 · 2018: 299 · 2017: 289 · 2016: 257 · 2015: 251 · 2014: 221 · 2013: 193 · 2012: 154
- FWCI
- 6.19
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- 5-fluorouracil, mechanism of action, drug resistance, predictive biomarkers, chemotherapeutic target, anticancer activity, cancer chemotherapy
- MeSH terms
- Animals, Antimetabolites, Antineoplastic, Fluorouracil, Humans, Interferons, Oxidoreductases, RNA, Thymidine Phosphorylase, Thymidylate Synthase, Biomarkers, Tumor Suppressor Protein p53, Microsatellite Repeats, Oligonucleotide Array Sequence Analysis, Dihydrouracil Dehydrogenase (NADP)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.